Tag: 106-52-5

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.106-52-5,1-Methylpiperidin-4-ol,as a common compound, the synthetic route is as follows.

Compound 1-methyl-4-piperidinol (1.26 g, 11 mmol) and NaH (240 mg, 12 mmol), were added into a round-bottom flask using DMF as a solvent. The mixture was stirred in ice water bath for 30 min, and 2-fluoro-5-nitrotrifluorotoluene (2.09 g , 10 mmol) was added, and the reaction was carried out at room temperature for 12 hours. The product 1-methyl-4-(4-nitro-2-(trifluoromethyl)phenylhydroxy)piperidine (2.9 g, yield: 95%) was obtained by purification.

The synthetic route of 106-52-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Shanghai Institute of Materia Medica, Chinese Academy of Sciences; HU, Youhong; GENG, Meiyu; REN, Wenming; DING, Jian; GUAN, Xiaocong; AI, Jing; WANG, Lang; PENG, Xia; LIU, Yang; DAI, Yang; ZENG, Limin; (45 pag.)EP3584239; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.106-52-5,1-Methylpiperidin-4-ol,as a common compound, the synthetic route is as follows.

a) S-Bromo-e-il-methyl-piperidin^-yloxyJ-imidazotl^-i lpyridazine To a suspension of NaH (60% in oil, 0.17 g, 4.31 mmol) in dry THF (5 mL) at 0 C was added a solution of 4-hydroxy-/V-methyl piperidine (0.50 g, 4.31 mmol) in dry THF (5 mL). The reaction mixture was stirred a 0C for 5 min then at RT for 15 min. The reaction mixture was cooled back to 0C and a solution of 3-bromo-6-chloroimidazo[1 ,2- ?>]pyridazine (0.50 g, 2.15 mmol) in dry THF (10 mL) was added dropwise. The reaction mixture was then allowed to warm up slowly to RT and stirred for 4 h. The reaction mixture was quenched by addition of water (10 mL), diluted with EtOAc (100 mL) and washed with water (2 x 50 mL). The organic layer was dried and concentrated in vacuo. Purification by column chromatography (EtOAc-2M NH3 in MeOH 5-100%) gave a solid (0.35 g, 53%); 1H NMR (400 MHz, DMSO-d6) delta ppm 8.04 (d, J=9.6 Hz, 1 H), 7.73 (s, 1H), 6.93 (d, J=9.6 Hz, 1 H), 4.99 (m, 1 H), 2.75-2.56 (m, 2H), 2.27-2.13 (m, 5H), 2.13-2.01 (m, 2H), 1.90-1.65 (m, 2H); m/z (ES+APCI)+: 311/313 [M+H]+.

The synthetic route of 106-52-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MEDICAL RESEARCH COUNCIL TECHNOLOGY; OSBORNE, Simon; CHAPMAN, Timothy; LARGE, Jonathan; BOULOC, Nathalie; WALLACE, Claire; WO2011/101640; (2011); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem